Biotechnology
WeTrade Group Inc. Ready to kick-off a Strategic Partnership with Zhixun Bio through WeTrade's SaaS platform and its the Internet of Things (IoT)
BEIJING, Aug. 18, 2022 /PRNewswire/ -- WeTrade Group Inc. ("WeTrade" or the "Company") (NASDAQ: WETG), an emerging growth company engaged in the business of providing software-as-a-services (SAAS) and cloud intelligent systems for micro-businesses, today announced the Company is in an advanced di...
2022-08-18 20:23
2221
Jemincare Announces Exclusive License Agreement with Genentech to Develop and Commercialize Novel Oral Androgen Receptor Degrader
SHANGHAI, Aug. 18, 2022 /PRNewswire/ -- Jemincare, a leading pharmaceutical company fromChina, announced today that it and its wholly owned subsidiary company, Shanghai Jemincare Pharmaceutical Co., Ltd., have entered into an exclusive worldwide license agreement with Roche (SIX: RO, ROG; OTCQX: ...
2022-08-18 15:25
2658
Zylox-Tonbridge maintains strong revenue and gross profit growth, including gross margin improvement driven by its platform-based strategy in 1H22
HANGZHOU, China, Aug. 18, 2022 /PRNewswire/ -- On August 15, Zylox-Tonbridge (2190.HK, "the Company") released its 2022 interim results. The Company's revenue increased 113.7% YoY to RMB 1.53 billion in the first six months of 2022. The revenue of neurovascular interventional products business i...
2022-08-18 14:57
1755
TurtleTree Announces LF+, the First-Ever Sustainable Lactoferrin Made With Precision Fermentation
WOODLAND, Calif. and SINGAPORE, Aug. 17, 2022 /PRNewswire/ -- Following 18
months of extensive R&D, TurtleTree has officially announced its production of
LF+, the world's first sustainable bovine lactoferrin created using precision
fermentation technology.
2022-08-17 22:00
4416
WuXi Biologics Reports Strong 2022 Interim Results
Revenue Increased by 63.5% Y-o-Y to RMB7,206.4 Million Gross Profit Increased by 48.6% Y-o-Y to RMB3,413.2 Million Net Profit Grew by 39.2% Y-o-Y to RMB2,621.2 Million Adjusted Net Profit Rose by 60.9% to RMB2,914.9 Million Total Backlog Reached US$18,467 Million * * * Non-COVID Re...
2022-08-17 21:32
3546
Novavax Nuvaxovid™ COVID-19 Vaccine Granted Expanded Provisional Approval in New Zealand as a First and Second Booster for Adults
* Nuvaxovid™ is New Zealand's first and only protein-based COVID-19 vaccine * Nuvaxovid™ can now be used as a first or second booster dose for adults aged 18 and older vaccinated with any primary series vaccine GAITHERSBURG, Md., Aug. 17, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a bi...
2022-08-17 20:00
3220
JOYSBIO HAS DEVELOPED NEW MONKEYPOX RAPID TESTS
JOYSBIO, one of the world's leading manufacturers of rapid test kits, has developed two new Monkeypox tests that deliver results in 15 minutes TIANJIN, China, Aug. 17, 2022 /PRNewswire/ -- JOYSBIO, one of the world's leading manufacturers of lateral flow rapid test kits, is proud to announce the...
2022-08-17 14:30
2935
Global Cord Blood Corporation Files Annual Report on Form 20-F
HONG KONG, Aug. 17, 2022 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"),China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced that the Company filed its Annual ...
2022-08-17 04:16
3010
Kronos Bio and Invivoscribe Partner on Companion Diagnostic for Use with Entospletinib, Kronos Bio's Investigational Compound Being Developed for Patients with AML
Companion diagnostic would be used following potential regulatory approval of entospletinib to screen for NPM1 mutation present in approximately one-third of all patients with AML Entospletinib is currently being studied in the Phase 3 AGILITY registrational study, with data anticipated in seco...
2022-08-17 04:05
3014
WuXi STA Breaks Ground for New Pharmaceutical Manufacturing Facility in Middletown, Delaware
MIDDLETOWN, Del., Aug. 16, 2022 /PRNewswire/ -- WuXi STA, a leading Contract Research, Development, and Manufacturing Organization (CRDMO), is pleased to announce the groundbreaking for its new 190-acre pharmaceutical manufacturing campus inMiddletown, Delaware. First announced in June 2021, this...
2022-08-17 01:47
4496
Medison Pharma Announces the Expansion of its Partnership with Albireo to a Multi-Regional Agreement to Commercialize Odevixibat in Canada and Israel
PETACH TIKVAH, Israel, Aug. 16, 2022 /PRNewswire/ -- Medison Pharma
2022-08-16 19:30
2502
Profitable growth continues: Exyte with remarkable 6M/2022 results and uplifted year-end outlook
- Order intake rose by almost 50 percent year-on-year, marking a new 6M-high with €4.7 billion - Sales volume increased by almost 50 percent to €3.4 billion - Adjusted EBIT increased by approximately two thirds to €202 million; adjusted EBITDA rose to €222 million, plus over 60 percent - Global...
2022-08-16 16:24
2506
ExoCoBio's First Global Regenerative Aesthetic Exosome Summit
* World First Regenerative Aesthetic Exosome Summit (RAES 2022) * Participation of Global Exosome and Regenerative Aesthetic Authorities * Plan to Grow into a Global Platform for Exosome and Regenerative Aesthetic Industry in the Future SEOUL, South Korea, Aug. 16, 2022 /PRNewswire/ -- ExoCo...
2022-08-16 15:00
6342
Sirnaomics Develops Peptide Docking Vehicle (PDoV(TM)) Designed for an Enhanced GalNAc Delivery Platform for Novel siRNA Therapeutics
A proprietary GalNAc delivery system with enhanced Endosome Escape and Dual-Targeting GAITHERSBURG, Md. and SUZHOU, China, Aug. 16, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi ...
2022-08-16 14:48
3031
J INTS BIO, Oral presentation of Preclinical results of its Novel Oral 4th Generation EGFR TKI 'JIN-A02' at the 2022 World Conference on Lung Cancer in Vienna, Austria (IASLC 2022 WCLC)
SEOUL, South Korea, Aug. 16, 2022 /PRNewswire/ -- J INTS BIO announced that the pre-clinical data of its novel, orally administered 4th generation EGFR TKI 'JIN-A02' was presented on the 8th of August, at the 2022 IASLC World Conference on Lung Cancer held inVienna, Austria, during the official s...
2022-08-16 13:35
1675
Antengene Announces First Patient Dosed of Small Molecule ATR ATG-018 for the Treatment of Patients with Advanced Solid Tumors and Hematologic Malignancies in Australia
* ATG-018, a global rights asset developed by Antengene's internal R&D team, is anorally-bioavailable, small molecule ataxia telangiectasia and Rad3-associated (ATR) kinase inhibitorthat targets the DNA damage response (DDR) pathways. * The Phase I study will evaluate the safety, pharmacology...
2022-08-16 08:30
2955
Bridge Biotherapeutics Receives FDA Authorization to Proceed with Phase 2 Study of BBT-877
* BBT-877 is intended to explore its treatment efficacy in idiopathic pulmonary fibrosis patients in a Phase II trial expected to start in 2022 SEONGNAM, South Korea, Aug. 15, 2022 /PRNewswire/ -- Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotechnology company developing ...
2022-08-16 08:17
1944
Everest Medicines Enters into Agreement with Gilead Sciences for Trodelvy in Asia Territories
Everest to receive total considerations of up to $455 million with $280 million in upfront payments Broadens development and access to Trodelvy for patients in Greater China and certain Asia Pacific Markets Strengthens balance sheet and streamlines resources to advance robust pipeline of first-...
2022-08-16 07:15
3157
ROKIT Healthcare to Enable Innovation in Treatment of Diabetes Foot and Osteoarthritis Combining AI and 3D Bioprinting on Google Cloud
SEOUL, South Korea, Aug. 15, 2022 /PRNewswire/ -- ROKIT Healthcare, a company specializing in bio-healthcare, today announced it will provide a hyper-personalized medical platform that uses 3D bioprinting and AI technology built on Google Cloud, to innovate the treatment of osteoarthritis and dia...
2022-08-15 07:00
4942
Novavax Nuvaxovid™ COVID-19 Vaccine Approved in South Korea for Use in Adolescents Aged 12 Through 17
* Novavax and partner SK bioscience will provide the first protein-based COVID-19 vaccine approved for use in adolescents aged 12 through 17 years in South Korea GAITHERSBURG, Md., Aug. 12, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and co...
2022-08-12 21:39
10369
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
QDX Co-Founder Giuseppe Barca Awarded Prestigious Gordon Bell Prize, Pioneering Advancements in Drug Discovery Technology
[Picked up by 297 media titles]
2024-11-26 18:49Southeast Asian Consumers Raise Online Security Concerns, New GSMA Survey Shows
[Picked up by 293 media titles]
2024-11-26 13:00Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
9300
Chinese path to modernization a model for Global South, experts say
2024-11-23 15:35
8507
